| Project/Area Number |
26293353
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kyushu University (2015-2016)
Kumamoto University (2014) |
|---|
Principal Investigator |
Eto Masatoshi 九州大学, 医学(系)研究科(研究院), 教授 (90315078)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
河野 吉昭 熊本大学, その他の研究科, 講師 (30593793)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NISHIMURA Yasuharu 熊本大学, 大学院生命科学研究部, 教授 (10156119)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥15,860,000 (Direct Cost: ¥12,200,000、Indirect Cost: ¥3,660,000)
Fiscal Year 2016: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2014: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
|---|
| Keywords | 癌 / 免疫学 / トランスレーショナルリサーチ |
|---|
| Outline of Final Research Achievements |
In this study, we have succeeded in identifying 4 long peptides (LPs) that comprise from 22-29 amino acids originated from Bladder cancer tumor-associated antigens (TAA). We confirmed the immunogenecity of LPs from Bladder cancer TAA (TAA-LP) by induction of TAA-LP-specific helper T (Th) cells from healthy donors. We could also detect type 1 Th (Th1) cells specific for TAA-LPs from Bladder cancer patients. Using transgenic mice expressing human HLA-A2, we next showed the induction of cytotoxic T cells (CTLs) specific for short peptides (SPs) from Bladder cancer TAA (TAA-SP), even after immunization with TAA-LPs, indicating the cross-presentation to Th cells and CTLs by TAA-LPs. We also succeeded in the enhancemant of CTLs against TAA-SPs when combined with LPs, Th clones, and anti-PD-1 mAb, implicating the new strategy of combination therapy with TAA-LPs. The above results have indicated that TAA-LPs are effective, and can be a new treatment option for patients with Bladder cancer.
|
